MannKind Corp. Stock
MannKind Corp. Stock
The price for the MannKind Corp. stock decreased slightly today. Compared to yesterday there is a change of -€0.014 (-0.410%).
With 28 Buy predictions and not a single Sell prediction MannKind Corp. is an absolute favorite of our community.
With a target price of 7 € there is potential for a 108.46% increase which would mean more than doubling the current price of 3.36 € for MannKind Corp..
So far the community has only identified positive things for MannKind Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of MannKind Corp. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -0.410% | -1.928% | -10.262% | -1.002% | -31.914% | -16.778% | -3.228% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind’s Phase 1b trial met its short-term safety and tolerability objective in 27 IPF patients, with no
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind received FDA approval for Furoscix ReadyFlow, an auto-injector that delivers an 80 mg dose of
What This MannKind Filing Reveals About Three Years of Underperformance
Sanjay R. Singh, EVP Technical Operations at MannKind Corporation (NASDAQ:MNKD), disposed of 46,795 shares of common stock on July 15, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction
